Grail, the San Francisco company that has raised $1.6 billion to develop a blood test to detect cancer, announced Thursday that it had appointed Hans Bishop, previously the CEO of Juno Therapeutics, as its new chief executive.

Bishop, who led Juno until it was sold to Celgene for $9 billion in March 2018, will be the third chief executive Grail has had since it was founded in 2015. He will replace Jennifer Cook, a former Roche executive; Grail said Cook was leaving the CEO job for family health reasons.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy